Log In
Print
BCIQ
Print
Print this Print this
 

Vernakalant (IV) (Brinavess, Kynapid) (MK-6621)

Also known as: formerly RSD1235 IV

  Manage Alerts
Collapse Summary General Information
Company Cardiome Pharma Corp.
DescriptionMixed ion channel antagonist
Molecular Target Not available
Mechanism of ActionNA
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationFibrillation
Indication DetailsTreat acute atrial fibrillation (AF)
Regulatory Designation
Partner AOP Orphan Pharmaceuticals AG; Aspen Pharmacare Holdings Ltd.; Eddingpharm Inc.; Eurolab Especialidades Medicinales de Eurofar s.r.l.; Logista Pharma S.A.; Phoenix Pharmahandel GmbH & Co. KG; Tzamal Medical Group Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

11

$821.6M

$73.0M

$640.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today